How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/individualized-pharmacokinetically-driven-paclitaxel-dosing.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Individualized pharmacokinetically driven paclitaxel dosing — Competitive Intelligence Brief

Individualized pharmacokinetically driven paclitaxel dosing (Individualized pharmacokinetically driven paclitaxel dosing) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane (paclitaxel) with pharmacokinetically guided dosing. Area: Oncology.

phase 3 Taxane (paclitaxel) with pharmacokinetically guided dosing Microtubule stabilizer (paclitaxel binds β-tubulin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Individualized pharmacokinetically driven paclitaxel dosing (Individualized pharmacokinetically driven paclitaxel dosing) — Central European Society for Anticancer Drug Research. Individualized pharmacokinetically driven paclitaxel dosing optimizes chemotherapy exposure by adjusting paclitaxel doses based on each patient's real-time drug clearance and pharmacokinetic parameters.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Individualized pharmacokinetically driven paclitaxel dosing TARGET	Individualized pharmacokinetically driven paclitaxel dosing	Central European Society for Anticancer Drug Research	phase 3	Taxane (paclitaxel) with pharmacokinetically guided dosing	Microtubule stabilizer (paclitaxel binds β-tubulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane (paclitaxel) with pharmacokinetically guided dosing class)

Central European Society for Anticancer Drug Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Individualized pharmacokinetically driven paclitaxel dosing — Competitive Intelligence Brief. https://druglandscape.com/ci/individualized-pharmacokinetically-driven-paclitaxel-dosing. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab